DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?

DENTSPLY SIRONA Inc. XRAY is scheduled to release second-quarter 2025 results on Aug. 7, before the opening bell.In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate. It delivered an average earnings surprise of 2.73% in the past four quarters.XRAY’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $851.6 million. The consensus mark for earnings is pinned at 29 cents per share.Factors to Note Ahead of XRAY’s Q2 ResultsDentsply Sirona heads into second-quarter earnings release amid a complex business recalibration, navigating both bright spots in product innovation and persistent macroeconomic pressures. A notable positive is the sustained global momentum in Imaging, bolstered by the relaunch of Orthophos SL and the introduction of Primescan 2. These efforts might have revitalized scanner volumes, particularly in Europe and APAC, where execution improvements likely translated into growth above expectations. Imaging’s resilience might have been a highlight during the to-be-reported quarter.In Orthodontics, SureSmile is expected to post another quarter of stable global growth, potentially driven by robust gains in Europe. However, U.S. performance is likely to have remained challenged due to softer discretionary spending and lingering competitive pressures. The company's strategic redeployment of Byte’s demand generation and software resources to SureSmile might have aided growth, but Byte’s weakness is likely to have continued to weigh on top-line performance.The suspension of Byte aligner sales, coupled with associated customer refunds, must have remained a substantial headwind, with Byte expected to negatively impact organic sales by approximately two percentage points in 2025. Second-quarter results are also likely to reflect a similar impact.Essential Dental Solutions benefited from stable patient traffic in first-quarter, especially in Rest of World markets, a similar trend likely to have continued in the second quarter. The adoption of new product launches like the X-Smart Pro+ Motor and Reciproc Blue files in the United States may have driven competitive conversions in soon-to-be-reported quarter. However, softness in elective procedures globally, coupled with lower lab volumes and weak U.S. implant sales, is likely to have capped broader segment growth.Connected Technology Solutions, including CAD/CAM, continues to face macroeconomic and pricing pressures, particularly in North America. While Germany delivered sequential CAD/CAM growth, U.S. CAD/CAM retail demand remained subdued, even amid the Primescan 2 launch, reflecting cautious capital spending by dental practices. Segmental sales growth is likely to have been weak during the second quarter.Operationally, Dentsply Sirona’s Phase II transformation activities, including foundational cost initiatives and SKU rationalization, are on track to deliver full run-rate savings by the end of 2025. Gross margins, pressured in the first quarter by Byte-related impacts, are expected to stabilize gradually through the year as volume ramps and restructuring savings flow through, implying a potential improvement in the second quarter.DENTSPLY SIRONA Inc. Price and EPS Surprise DENTSPLY SIRONA Inc. price-eps-surprise | DENTSPLY SIRONA Inc. QuoteWhat the Zacks Model Unveils for XRAYOur proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.XRAY’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.99%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #2.Stocks to ConsiderCardinal Health, Inc. CAH, Cencora, Inc. COR and McKesson Corporation MCK are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.Cardinal Health has an Earnings ESP of +0.72% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 10.9%.Cardinal Health’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.3%.Cencora has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. COR has an estimated long-term growth rate of 12.80%.Cencora’searnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%.McKessonhas an Earnings ESP of +0.14% and a Zacks Rank of 2 at present. MCK has an estimated long-term growth rate of 13.3%.McKesson’searnings surpassed estimates in three of the trailing four quarters and missed in one, with the average surprise being 3.9%.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks